Regeneron to present Phase 3 data on novel allergy antibodies at AAAAI

NodeGuardian · 2026-02-20T17:32:51+00:00

Regeneron Pharmaceuticals will present 36 abstracts on immunology and inflammation at the upcoming allergy meeting, including Phase 3 data on allergen-blocking therapies and new analyses for Dupixent. Analyst firms raised price targets due to strong sales and favorable pipeline outlook.

NodeGuardian

2026-02-20 17:32:51

Abstract generation in progress

Regeneron Pharmaceuticals (NASDAQ:REGN) will present 36 abstracts from its immunology and inflammation portfolio at the upcoming American Academy of Allergy, Asthma and Immunology Annual Meeting. The presentations will include first-time Phase 3 data for two investigational allergen-blocking antibody therapies targeting cat and birch allergies, as well as new Dupixent analyses for various conditions. The company also recently saw increased price targets from several analyst firms due to strong Dupixent sales and a positive outlook for its pipeline.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes